| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shi-Fu Xiao, Hai-Bo Xue, Xia Li, Chao Chen, Guan-Jun Li, Cheng-Mei Yuan, Ming-Yuan Zhan. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. Neuroscience bulletin. vol 27. issue 4. 2011-12-06. PMID:21788997. |
objective to identify whether sarsasapogenin, a sapogenin from the chinese medicinal herb anemarrhena asphodeloides bunge, would augment the efficacy of risperidone and significantly improve cognitive functions in patients with negative symptoms dominated schizophrenia. |
2011-12-06 |
2023-08-12 |
human |
| Shi-Fu Xiao, Hai-Bo Xue, Xia Li, Chao Chen, Guan-Jun Li, Cheng-Mei Yuan, Ming-Yuan Zhan. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. Neuroscience bulletin. vol 27. issue 4. 2011-12-06. PMID:21788997. |
conclusion sarsasapogenin did not augment the efficacy of risperidone in treating negative symptoms dominated schizophrenia. |
2011-12-06 |
2023-08-12 |
human |
| Shi-Fu Xiao, Hai-Bo Xue, Xia Li, Chao Chen, Guan-Jun Li, Cheng-Mei Yuan, Ming-Yuan Zhan. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. Neuroscience bulletin. vol 27. issue 4. 2011-12-06. PMID:21788997. |
sarsasapogenin at a dosage of 200 mg per day added to a flexible dosage of risperidone at 2-4 mg per day is safe and well tolerated by patients with negative symptoms dominated schizophrenia. |
2011-12-06 |
2023-08-12 |
human |
| Alessandro Zuddas, Roberta Zanni, Tatiana Usal. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 21. issue 8. 2011-11-28. PMID:21550212. |
sgas efficacy on mania, extreme mood variability, irritability, aggression and disruptive behavior appears to be greater than for psychotic symptoms in schizophrenia: average nnt was 2-5, whereas for schizophrenia it varies between 3 for risperidone and 10 for olanzapine, quetiapine, and aripiprazole. |
2011-11-28 |
2023-08-12 |
Not clear |
| Paul G Barnett, Jennifer Y Scott, Robert A Rosenhec. How do clinical trial participants compare to other patients with schizophrenia? Schizophrenia research. vol 130. issue 1-3. 2011-11-23. PMID:21514794. |
patients with schizophrenia enrolled in a trial of long-acting injectable risperidone at multiple sites of the veterans health administration (vha). |
2011-11-23 |
2023-08-12 |
human |
| Vishal Madaan, Durga P Bestha, Venkata Kolli, Saurabh Jauhari, Roger C Burke. Clinical utility of the risperidone formulations in the management of schizophrenia. Neuropsychiatric disease and treatment. vol 7. 2011-11-23. PMID:22090797. |
clinical utility of the risperidone formulations in the management of schizophrenia. |
2011-11-23 |
2023-08-12 |
human |
| Vishal Madaan, Durga P Bestha, Venkata Kolli, Saurabh Jauhari, Roger C Burke. Clinical utility of the risperidone formulations in the management of schizophrenia. Neuropsychiatric disease and treatment. vol 7. 2011-11-23. PMID:22090797. |
risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. |
2011-11-23 |
2023-08-12 |
human |
| Ichiro Kusumi, Minoru Honda, Koichi Ito, Keiichi Uemura, Yukie Kumazawa, Tomohito Ishikane, Yasushi Niide, Tsukasa Koyam. Risperidone oral solution versus standard tablets for the acute treatment of patients with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 2. 2011-11-22. PMID:21168464. |
risperidone oral solution versus standard tablets for the acute treatment of patients with schizophrenia. |
2011-11-22 |
2023-08-12 |
Not clear |
| Chikako Ohta, Norio Yasui-Furukori, Hanako Furukori, Shoko Tsuchimine, Manabu Saito, Taku Nakagami, Kaori Yoshizawa, Sunao Kanek. The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 2. 2011-11-22. PMID:21216266. |
the effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. |
2011-11-22 |
2023-08-12 |
human |
| Chikako Ohta, Norio Yasui-Furukori, Hanako Furukori, Shoko Tsuchimine, Manabu Saito, Taku Nakagami, Kaori Yoshizawa, Sunao Kanek. The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 2. 2011-11-22. PMID:21216266. |
subjects included 154 schizophrenia patients (61 males, 93 females) who had received 3 mg of risperidone twice daily for at least 4 weeks. |
2011-11-22 |
2023-08-12 |
human |
| Chien-Chih Chen, Tiao-Lai Huan. Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry research. vol 189. issue 3. 2011-11-15. PMID:21320726. |
specifically, this study measured serum bdnf levels in 53 patients with paranoid schizophrenia during a relapse and again 4 weeks following the administration of antipsychotic treatment (with risperidone in 32 cases, and clozapine in 21 cases). |
2011-11-15 |
2023-08-12 |
human |
| Maximilian Gahr, Markus A Kölle, Carlos Schönfeldt-Lecuona, Peter Lepping, Roland W Freudenman. Paliperidone extended-release: does it have a place in antipsychotic therapy? Drug design, development and therapy. vol 5. 2011-11-15. PMID:21448450. |
paliperidone (9-hydroxy-risperidone), the active metabolite of risperidone, was approved for treating schizophrenia worldwide in 2006 as paliperidone extended-release (per), and became the first second-generation antipsychotic specifically licensed for treating schizoaffective disorder in 2009. |
2011-11-15 |
2023-08-12 |
Not clear |
| Fabrice Bon, Eric Louis Constant, Peter Goethals, Daniel Ne. Absence of cardiac side effects during treatment of schizophrenia with risperidone in a patient with wolff-Parkinson-white syndrome. Primary care companion to the Journal of clinical psychiatry. vol 9. issue 3. 2011-11-10. PMID:17632661. |
absence of cardiac side effects during treatment of schizophrenia with risperidone in a patient with wolff-parkinson-white syndrome. |
2011-11-10 |
2023-08-12 |
Not clear |
| Kenan M Penaskovic, Fasiha Haq, Shakeel Raz. Priapism during treatment with olanzapine, quetiapine, and risperidone in a patient with schizophrenia: a case report. Primary care companion to the Journal of clinical psychiatry. vol 12. issue 5. 2011-11-10. PMID:21274367. |
priapism during treatment with olanzapine, quetiapine, and risperidone in a patient with schizophrenia: a case report. |
2011-11-10 |
2023-08-12 |
Not clear |
| John P Redrobe, Sascha Bull, Niels Plat. Translational Aspects of the Novel Object Recognition Task in Rats Abstinent Following Sub-Chronic Treatment with Phencyclidine (PCP): Effects of Modafinil and Relevance to Cognitive Deficits in Schizophrenia. Frontiers in psychiatry. vol 1. 2011-11-10. PMID:21423454. |
the aim of the present study was to investigate the effects of selected antipsychotic and cognition enhancing drugs, namely haloperidol, risperidone, donepezil, and modafinil in an animal model widely used in preclinical schizophrenia research. |
2011-11-10 |
2023-08-12 |
rat |
| Mário Rodrigues Louzã, Helio Elkis, Sandra Ruschel, Irismar Reis de Oliveira, Rodrigo Affonseca Bressan, Paulo Belmonte-de-Abreu, Hamilton Grabowski, José Carlos Appolinári. Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia. Neuropsychiatric disease and treatment. vol 7. 2011-11-10. PMID:21822391. |
long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia. |
2011-11-10 |
2023-08-12 |
Not clear |
| William Victor Bobo, Stefania Bonaccorso, Karuna Jayathilake, Herbert Yale Meltze. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. Psychiatry research. vol 189. issue 2. 2011-11-08. PMID:21802150. |
prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. |
2011-11-08 |
2023-08-12 |
Not clear |
| Y-T Xiang, C-Y Wang, G S Ungvari, J A Kreyenbuhl, H F K Chiu, K Y C Lai, E H M Lee, Q-J Bo, L B Dixo. Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. Pharmacopsychiatry. vol 44. issue 4. 2011-10-27. PMID:21710403. |
weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. |
2011-10-27 |
2023-08-12 |
Not clear |
| Y-T Xiang, C-Y Wang, G S Ungvari, J A Kreyenbuhl, H F K Chiu, K Y C Lai, E H M Lee, Q-J Bo, L B Dixo. Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. Pharmacopsychiatry. vol 44. issue 4. 2011-10-27. PMID:21710403. |
this study aimed to characterize weight changes in schizophrenia patients taking risperidone as part of a randomized, controlled, open-label clinical trial. |
2011-10-27 |
2023-08-12 |
Not clear |
| Sonia Dollfu. Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline. Evidence-based mental health. vol 14. issue 3. 2011-10-26. PMID:21764878. |
effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline. |
2011-10-26 |
2023-08-12 |
Not clear |